Prime Medicine Peer Comparison
$2.90
$-0.17
(-5.54%)
As on 25-Sep-2026 16:21EDT
Market cap
$526 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Edit
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
526 | 2,804 | 2,423 | 1,963 | 727 |
Revenue ($ Mln) |
4 | 450 | 549 | 121 | -- |
Net Profit ($ Mln) |
-187.89 | -188.21 | 17.88 | -57.76 | -175.85 |
Net Margin (%) |
-4,613.11 | -41.86 | 3.26 | -47.82 | -- |
RoE (%) |
-233.88 | -28.46 | 1.43 | -9.91 | -106.84 |
Price to Earnings |
-- | -- | 139.40 | -- | -- |
Price-To-Book |
0.28 | 4.89 | 1.98 | 3.50 | 4.97 |
Income Statement ($ Mln)
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4.07 | 449.61 | 549.12 | 120.25 | 0.00 |
|
Cost of Revenue
|
47.72 | 195.71 | 548.01 | 19.21 | 12.78 |
|
Gross Profit
|
-2.69 | 269.08 | 212.72 | 12.07 | -17.67 |
|
Operating Expenses
|
154.75 | 517.90 | 35.89 | 154.86 | 176.86 |
|
Operating Profit (EBIT)
|
-196.52 | -264.00 | -34.78 | -51.50 | -181.14 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-187.89 | -190.72 | 20.08 | -57.14 | -178.93 |
|
Provision for Tax
|
0.00 | -2.51 | 1.66 | 0.62 | -3.09 |
|
Profit after Tax (Net Income)
|
-187.89 | -188.21 | 17.88 | -57.50 | -175.85 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
39.81 | 607.04 | 1,260.78 | 568.41 | 160.40 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
177.54 | 39.17 | 186.25 | 123.56 | 8.50 |
|
Current Liabilities
|
31.69 | 428.58 | 275.21 | 81.11 | 54.30 |
|
Total Liabilities
|
342.73 | 1,172.38 | 1,753.10 | 784.68 | 233.72 |
Assets ($ Mln)
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
152.24 | 160.76 | 183.02 | 575.59 | 21.30 |
|
Current Assets
|
96.80 | 914.04 | 1,553.41 | 197.49 | 201.90 |
|
Total Assets
|
342.73 | 1,172.38 | 1,753.10 | 784.68 | 233.72 |
|
Total Debt*
|
112.48 | 254.58 | 94.51 | 127.33 | 21.00 |
|
Net Current Assets
|
65.11 | 485.45 | 0.00 | 116.38 | 147.60 |
Cashflow ($ Mln)
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-162.56 | -150.79 | -64.66 | -49.95 | -121.18 |
|
Cash Flow from Investing Activities
|
-108.76 | 307.87 | -29.41 | 0.12 | -1.37 |
|
Cash from Financing Activities
|
151.51 | 72.35 | 7.84 | 147.34 | 276.18 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-93.29 | -18.15 | 41.92 | -15.42 | -130.25 |
|
ROE (%)
|
-233.88 | -28.46 | 1.43 | -10.06 | -106.84 |
|
ROA (%)
|
-63.28 | -12.55 | 0.66 | -6.60 | -74.77 |
|
EBIT Margin (%)
|
-4,613.11 | -41.09 | -6.33 | -42.62 | -- |
|
Net Margin (%)
|
-4,613.11 | -41.86 | 3.26 | -47.82 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | -- | -- | -- |
Growth Ratios
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-17.90 | 5.10 | -8.81 | 599.21 | -1.00 |
|
EBIT Growth (%)
|
5.71 | 11.36 | -76.55 | 17.93 | -45.21 |
|
Net Profit Growth (%)
|
5.71 | 11.44 | -96.17 | 43.71 | -43.04 |
|
EPS Growth (%)
|
28.69 | -1.87 | -96.17 | 47.43 | 7.30 |
|
Book Value Growth (%)
|
-52.32 | -25.05 | 2.54 | -6.65 | 108.85 |
Valuation Ratios
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-2.57 | -11.11 | 5.08 | -13.58 | -9.99 |
|
Price / Book Value
|
0.28 | 4.89 | 1.98 | 3.50 | 4.97 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
EV/EBITDA
|
-2.57 | -13.86 | -56.23 | -45.40 | -3.22 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.19 | 0.00 |
|
Short term debt to equity ratio
|
0.23 | 0.40 | 0.02 | 0.02 | 0.09 |
|
Current Ratio
|
3.05 | 2.13 | 5.64 | 2.43 | 3.72 |
|
Quick Ratio
|
3.05 | 1.92 | 5.50 | 2.09 | 3.72 |
|
Interest Coverage
|
-- | -30.87 | -19.05 | -4.06 | -- |
Operating Efficiency Ratios
| Prime Medicine | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 16.23 | 21.41 | 47.46 | -- |
|
Asset Turnover
|
0.01 | 0.30 | 0.20 | 0.14 | 0.00 |
|
Receivable days
|
-- | 77.60 | 104.79 | 380.35 | -- |
|
Inventory Days
|
-- | 109.55 | 49.57 | 791.94 | -- |
|
Payable days
|
504.84 | 231.78 | 47.68 | 931.00 | 650.68 |
|
Cash Conversion Cycle
|
-- | -44.63 | 106.67 | 241.30 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
